ub.xmlui.mirage2.page-structure.muninLogoub.xmlui.mirage2.page-structure.openResearchArchiveLogo
    • EnglishEnglish
    • norsknorsk
  • Velg spraaknorsk 
    • EnglishEnglish
    • norsknorsk
  • Administrasjon/UB
Vis innførsel 
  •   Hjem
  • Det helsevitenskapelige fakultet
  • Institutt for medisinsk biologi
  • Artikler, rapporter og annet (medisinsk biologi)
  • Vis innførsel
  •   Hjem
  • Det helsevitenskapelige fakultet
  • Institutt for medisinsk biologi
  • Artikler, rapporter og annet (medisinsk biologi)
  • Vis innførsel
JavaScript is disabled for your browser. Some features of this site may not work without it.

The oncolytic peptide LTX-315 triggers immunogenic cell death

Permanent lenke
https://hdl.handle.net/10037/10551
DOI
https://doi.org/10.1038/cddis.2016.47
Thumbnail
Åpne
article.pdf (4.101Mb)
Main article (PDF)
Dato
2016-03-10
Type
Journal article
Tidsskriftartikkel
Peer reviewed

Forfatter
Zhou, Heng; Forveille, Sabrina; Sauvat, Allan; Yamazaki, T; Senovilla, L; Ma, Y; Liu, Peng; Yang, H; Bezu, L; Müller, K; Zitvogel, Laurence; Rekdal, Øystein; Kepp, Oliver; Kroemer, Guido
Sammendrag
LTX-315 is a cationic amphilytic peptide that preferentially permeabilizes mitochondrial membranes, thereby causing partially BAX/ BAK1-regulated, caspase-independent necrosis. Based on the observation that intratumorally injected LTX-315 stimulates a strong T lymphocyte-mediated anticancer immune response, we investigated whether LTX-315 may elicit the hallmarks of immunogenic cell death (ICD), namely (i) exposure of calreticulin on the plasma membrane surface, (ii) release of ATP into the extracellular space, (iii) exodus of HMGB1 from the nucleus, and (iv) induction of a type-1 interferon response. Using a panel of biosensor cell lines and robotized fluorescence microscopy coupled to automatic image analysis, we observed that LTX-315 induces all known ICD characteristics. This conclusion was validated by several independent methods including immunofluorescence stainings (for calreticulin), bioluminescence assays (for ATP), immunoassays (for HMGB1), and RT-PCRs (for type-1 interferon induction). When injected into established cancers, LTX-315 caused a transiently hemorrhagic focal necrosis that was accompanied by massive release of HMGB1 (from close-to-all cancer cells), as well as caspase-3 activation in a fraction of the cells. LTX-315 was at least as efficient as the positive control, the anthracycline mitoxantrone (MTX), in inducing local inflammation with infiltration by myeloid cells and T lymphocytes. Collectively, these results support the idea that LTX-315 can induce ICD, hence explaining its capacity to mediate immune-dependent therapeutic effects.
Beskrivelse
Published version. Source at http://dx.doi.org/10.1038/cddis.2016.47
Forlag
Nature Publishing Group
Sitering
Zhou, H. et.al.: The oncolytic peptide LTX-315 triggers immunogenic cell death. Cell Death & Disease. 2016, 7, e2134; doi:10.1038/cddis.2016.47
Metadata
Vis full innførsel
Samlinger
  • Artikler, rapporter og annet (medisinsk biologi) [1105]

Bla

Bla i hele MuninEnheter og samlingerForfatterlisteTittelDatoBla i denne samlingenForfatterlisteTittelDato
Logg inn

Statistikk

Antall visninger
UiT

Munin bygger på DSpace

UiT Norges Arktiske Universitet
Universitetsbiblioteket
uit.no/ub - munin@ub.uit.no

Tilgjengelighetserklæring